Alane P. Barnes

All filings by Alane P. Barnes on record concern Biocryst Pharmaceuticals Inc, in the capacity of senior executive. Over a trading history stretching from 1 January 2016 to 13 May 2026, the count stands at 22 filings.

In open-market terms, that means 1 purchase worth €26k on one side and 3 sales worth €694k on the other. Sales outweigh purchases by €668k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 13 share grants and 5 option exercises. 2026 to date brings no purchases and 1 sale.

Most recently, on 15 May 2026, the filings show an open-market sale worth €509k in Biocryst Pharmaceuticals Inc. The latest purchase dates back some time: it was published 886 days ago, on 15 May 2024. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.